8-K/A: Kiromic BioPharma Secures $1 Million in Financing via Convertible Promissory Note

Kiromic BioPharma issued a $1 million senior secured convertible promissory note to an accredited investor, with a 25% interest rate and potential conversion into common stock.

Summary

• Kiromic BioPharma, Inc. has entered into a material definitive agreement by issuing a 25% Senior Secured Convertible Promissory Note (the 'Note') to an accredited investor on January 28, 2025.
• The Note has a principal amount of $1,000,000 and bears interest at a rate of 25% per annum.
• The Note matures on January 28, 2026, at which point the principal balance and accrued interest are due and payable.
• The interest rate will increase to 27% upon an event of default, such as failure to make payments or commencement of bankruptcy proceedings.
• Beginning February 28, 2025, the holder has the right to convert the Note into shares of the company's common stock at a price equal to 90% of the 5-day VWAP, subject to a 19.99% beneficial ownership limitation.
• The Note represents unsubordinated obligations of the company and is senior to all subordinated indebtedness and equity securities.
• The obligations under the Note are secured by the company's fixtures, equipment, and intellectual property.
• Following this transaction, the holder possesses a total of $14.2 million in outstanding promissory notes, along with shares of Series C, D, and E Convertible Voting Preferred Stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company has secured funding, the high interest rate and potential dilution present risks.

Positives

• Kiromic BioPharma has secured $1 million in funding through the issuance of a convertible promissory note.
• The company retains the option to prepay the note before the maturity date without penalty or premium.

Negatives

• The high interest rate of 25% (potentially rising to 27% upon default) increases the cost of capital for Kiromic BioPharma.
• The conversion feature could lead to dilution of existing shareholders' equity.
• The note is secured by the company's assets, potentially limiting financial flexibility.

Risks

• Failure to make payments on the note could trigger an event of default, leading to an increased interest rate and potential acceleration of the debt.
• The conversion of the note into common stock could dilute existing shareholders' equity.
• The company's ability to raise additional capital may be limited by the existing debt and security interests.

Future Outlook

The company intends to use the proceeds from the note for the continued development of its multi-indication allogeneic CAR-T cell therapy and for other general corporate purposes.

Management Comments

• There are no direct management comments included in the document.

Industry Context

Biopharmaceutical companies often utilize convertible notes as a means of securing funding, particularly during the research and development phases. This type of financing allows companies to access capital while offering investors the potential for equity upside.

Comparison to Industry Standards

• The 25% interest rate on the convertible note is relatively high compared to industry standards, which typically range from 8% to 15% for similar financings.
• The conversion feature, allowing the holder to convert the debt into equity, is a common practice in the biopharmaceutical industry.
• The security interest granted to the holder, including fixtures, equipment, and intellectual property, is a standard provision in secured debt agreements.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into common stock.
• Employees may benefit from the funding, which supports the development of the company's CAR-T cell therapy.
• The company's creditors are subordinated to the holder of the note.

Next Steps

• Kiromic BioPharma will use the proceeds for the development of its CAR-T cell therapy and general corporate purposes.
• The holder may choose to convert the note into common stock starting February 28, 2025.
• The company is required to file a registration statement for the resale of the conversion shares.

Key Dates